216 related articles for article (PubMed ID: 7909337)
1. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
Zhang F; Dryhurst G
J Med Chem; 1994 Apr; 37(8):1084-98. PubMed ID: 7909337
[TBL] [Abstract][Full Text] [Related]
2. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease.
Shen XM; Dryhurst G
Chem Res Toxicol; 1996 Jun; 9(4):751-63. PubMed ID: 8831820
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease.
Shen XM; Xia B; Wrona MZ; Dryhurst G
Chem Res Toxicol; 1996; 9(7):1117-26. PubMed ID: 8902266
[TBL] [Abstract][Full Text] [Related]
4. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity.
Shen XM; Dryhurst G
Chem Res Toxicol; 1998 Jul; 11(7):824-37. PubMed ID: 9671546
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of dopamine in the presence of cysteine: characterization of new toxic products.
Shen XM; Zhang F; Dryhurst G
Chem Res Toxicol; 1997 Feb; 10(2):147-55. PubMed ID: 9049425
[TBL] [Abstract][Full Text] [Related]
6. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease.
Li H; Dryhurst G
J Neurochem; 1997 Oct; 69(4):1530-41. PubMed ID: 9326282
[TBL] [Abstract][Full Text] [Related]
7. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease.
Li H; Shen XM; Dryhurst G
J Neurochem; 1998 Nov; 71(5):2049-62. PubMed ID: 9798930
[TBL] [Abstract][Full Text] [Related]
8. Oxidation chemistry of (-)-norepinephrine in the presence of L-cysteine.
Shen XM; Dryhurst G
J Med Chem; 1996 May; 39(10):2018-29. PubMed ID: 8642560
[TBL] [Abstract][Full Text] [Related]
9. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex.
Li H; Dryhurst G
J Neural Transm (Vienna); 2001; 108(12):1363-74. PubMed ID: 11810401
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Han J; Cheng FC; Yang Z; Dryhurst G
J Neurochem; 1999 Oct; 73(4):1683-95. PubMed ID: 10501216
[TBL] [Abstract][Full Text] [Related]
11. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease.
Shen XM; Li H; Dryhurst G
J Neural Transm (Vienna); 2000; 107(8-9):959-78. PubMed ID: 11041275
[TBL] [Abstract][Full Text] [Related]
12. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra.
Fornstedt B; Brun A; Rosengren E; Carlsson A
J Neural Transm Park Dis Dement Sect; 1989; 1(4):279-95. PubMed ID: 2597314
[TBL] [Abstract][Full Text] [Related]
13. Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells.
Naoi M; Yi H; Maruyama W; Inaba K; Shamoto-Nagai M; Akao Y; Gerlach M; Riederer P
Neurosci Lett; 2009 Nov; 465(2):118-22. PubMed ID: 19737600
[TBL] [Abstract][Full Text] [Related]
14. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B
J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937
[TBL] [Abstract][Full Text] [Related]
15. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
[TBL] [Abstract][Full Text] [Related]
16. Drug treatment of Parkinson's disease. Time for phase II.
Drukarch B; van Muiswinkel FL
Biochem Pharmacol; 2000 May; 59(9):1023-31. PubMed ID: 10704931
[TBL] [Abstract][Full Text] [Related]
17. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
18. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
[TBL] [Abstract][Full Text] [Related]
19. The role of transition metals in the pathogenesis of Parkinson's disease.
Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
[TBL] [Abstract][Full Text] [Related]
20. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo.
Sidell KR; Olson SJ; Ou JJ; Zhang Y; Amarnath V; Montine TJ
J Neurochem; 2001 Nov; 79(3):510-21. PubMed ID: 11701754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
